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Abstract: 
Neuroinflammation and activation of innate immunity are early events in 
neurodegenerative diseases including Alzheimer’s disease (AD).  Recently, a rare 
mutation (R47H) in the gene Triggering receptor expressed on myeloid cells 2 
(TREM2) has been associated with a substantial increase in the risk of developing late 
onset Alzheimer’s disease. To uncover the molecular mechanisms underlying this 
association we investigated the RNA and protein expression of TREM2 in APP/PS1 
transgenic mouse brain (APP/PS1-tg2576).   
Our findings suggest that TREM2 not only plays a critical role in the inflammation, 
also plays a role in neuronal cell survival and in neurogenesis. We have shown that 
TREM2 is a soluble protein transported by macrophages through ventricle walls and 
choroid plexus then enters in the brain parenchyma via radial glial cells. TREM2 
protein is essential for neuroplasticity and myelination. Later in life lack of TREM2 
protein may accelerate ageing processes and neuronal cell loss and reduce microglial 
activity, ultimately that leads to neuroinflammation. As inflammation plays a major 
role in neurodegenerative diseases, a lack of TREM2 could be a missing link between 
immunomodulation and neuroprotection.  
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Introduction 
 
The immune system has evolved to defend against pathogens and clear up 
endogenous defective cells (plaques/dying neurons), it is thus conceivable that the 
immune system may be actively be involved in Alzheimer’ disease (AD). Molecules 
of both the innate and adaptive immune responses are induced in a wide range of 
neurological disorders, including AD [1, 2], Parkinson's disease (PD) [3-5], 
Huntington's disease [6], amyotrophic lateral sclerosis (ALS) [7], and multiple 
sclerosis [8]. There is a highly organized innate immune response during the early 
stages of inflammation. This inflammatory response is characterized by the 
expression of various immunological proteins in the circumventricular organs 
(CVOs), choroid plexus (CPs) and other structures lacking the protection conferred by 
the blood–brain barrier (BBB) [9, 10].  The response extends progressively to affect 
microglia and macrophages across the brain parenchyma and may lead to the onset of 
an adaptive immune response [11, 12].  
Alzheimer’s diseases (AD) is characterized by the presence of extracellular amyloid 
deposits comprised of aggregated β-amyloid (Aβ) peptides and intracellular 
neurofibrillary tangles containing hyperphosphorylated, aggregated tau protein [13, 
14].  The deposition of Aβ in brain areas involved in cognitive functions is assumed 
to initiate a pathological cascade that ultimately results in inflammation, synaptic 
dysfunction, synaptic loss and neuronal death [15, 16].  
Triggering receptor expressed on myeloid cells 2 (TREM2) is a 
microglia/macrophage receptor that acts as a sensor for a wide array of lipids 
including apolipoprotein (ApoE) and Phospholipid transfer protein (PLTP) [17-20]. 
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Recent genome-wide association studies have shown that a rare mutation (R47H) of 
TREM2 gene is associated with a substantial increase in the risk of developing AD 
[19-22].  The absence of TREM2 expression on microglia impairs their capacity to 
phagocytose cell membrane debris and increases their production of pro-inflammatory 
cytokines [23, 24]. Identification of this novel variant in the gene encoding for 
TREM2 has refocused attention onto inflammation as a major contributing factor in 
AD [25, 26].   DNAX-activating protein of 12kDa (DAP12, also called TYROBP) is a 
type I transmembrane adapter proteins which associates with the cytosolic portion of 
TREM2, forming a molecular complex [17, 27]. It is expressed in neurons, microglia 
and resident macrophages in the CNS [28] and functions to stimulate phagocytosis 
and to suppress cytokine production and inflammation [29]. Developmental dys-
regulation of either TREM2 or DAP12 mutation causes an early onset form of 
dementia with cystic bone disorder, known as Nasu-Hakola disease [30-32]. 
Several mouse models that mimic some of the neuropathological and behavioral 
features of AD have been developed [33-36].   Transgenic mice expressing human 
APP695 containing the double mutation Lys670-Asn, Met 671 Leu (Swedish 
mutation) and one PS1 mutation (M146V) in tg2576 (APP/PS1-tg2576) displays age-
dependent increases in Aβ plaques, activated microglia, and astrocytes and dystrophic 
neuritis [10, 16, 35, 37]. The effects of TREM2 in an AD mouse models, particularly 
those upon Aβ plaque load, have been studied in different transgenic mouse models, 
generating conflicting results; one group reported that the absence of TREM2 
decreased Aβ load [38] whereas another group reported that TREM2 deficiency 
increased Aβ deposit in another AD (5xFAD) mouse model [39].  Both groups 
showed the presence of TREM2 in the microglia or in the peripheral macrophages. 
However, none of these papers have mentioned of the TREM2 protein expression in 
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the neurons or other glial cells (e.g. in astrocytes or oligodendrocytes).  
The aim of our study was to investigate TREM2 protein expression in the APP-PS1 
transgenic mouse model of AD to validate both previous and novel findings regarding 
the location of TREM2 in mouse brain and in vitro analysis using primary neuron and 
glial culture. Collectively, our data demonstrates that in the young mouse brain 
TREM2 protein is expressed in pyramidal neurons and dentate gyrus granule cells, 
indicating a developmental role in neuronal cell survival and neurogenesis. During the 
early stages of the AD like phenotype in the APP-PS1 mice (between 3-6 months) 
activated microglia and astrocytes were visible close to the Aβ plaques but TREM2 
protein did not co-localised with microglial markers (Iba1 or CD11b) or GFAP 
positive astrocytes. Furthermore, we show that TREM2 protein levels decline with 
age that may affect neuronal survival. This may causes the failure of clearance of 
amyloid deposits by microglia in APP-PS1 mouse brain. 
 
Materials and methods  
Transgenic mice 
Transgenic mice over expressing the 695-amino acid isoform of human Alzheimer β-
amyloid (Aβ) precursor protein containing a Lys670 → Asn, Met671 → Leu mutation 
(K670N and V717F, Swedish mutation) and one PS1 mutation (M146V), driven by 
Thy1 promoter on a C57BL/6 genetic background (Tg2576) were purchased from 
Jackson Laboratory, USA. Neuropathological characterisation of these animals has 
previously been described in detail [10, 35]. At 3–4 months, these mice start 
accumulating amyloid deposition and plaques formation, by 9-12 months they 
resemble a more severe stage of AD pathology [10]. All animals were housed under 
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standard conditions (12h light-dark cycle, 20˚C ambient temperature) with free access 
to food and water. All procedures were performed under license in accordance to the 
UK Animals (Scientific Procedures) Act 1986. 
Six mice per age group (3, 6, 9 and 10-12 months-old) were used for RT-PCR, 
immunohistochemistry. Similarly, six mice from each group used for protein 
quantitation by Western blotting (WB), described subsequently. C57/BL mice were 
used as control samples (n=6, age-matched to APP-PS1 mice). 
Tissue preparation 
Mice were terminally anaesthetized with carbon dioxide and culled. Unfixed tissues 
were dissected from various brain regions from control and APP-PS1 mouse brains 
and snap frozen in dry ice until analyzed by either RT-PCR or Western blotting as 
described previously [40]. For histochemical analyses, animals were anesthetized with 
pento-barbitone and flash-perfused transcardially with 0.9% saline followed with 4% 
(v/v) paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). Brains were 
sectioned by microtome as described previously [41]. Free-floating sections were 
prepared (25µm coronal sections in 0.1 M PBS) through the entire olfactory bulb, 
hippocampus, cortex, mid brain and cerebellum. Sections were then stained by 
immunohistochemistry as described below.  
RNA isolation and RT-PCR 
For RNA analysis mouse brain (n = 6) tissues were dissected from frontal cortex (that 
also contains blood vessels and endothelium) as described above. RNA was extracted 
from approximately 50 mg of tissue and 1 ml of TRIzol reagent (Invitrogen) 
following manufacturer’s instructions and then purified using an RNeasy Mini kit 
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(Qiagen). RNA was treated with DNase I, and cDNA synthesised from 2 µg of the 
treated RNA using a SuperScript III reverse transcriptase kit (Invitrogen) with random 
hexamer primers. PCR of the newly synthesized cDNA (8 ng) was performed using 
PCR Supermix (Invitrogen) with the primer pairs for TREM2 (Forward Primer: 
GCTGCTGATCACAGCCCTG, and Reverse primer: 
CTTGATTCCTGGAGGTGCTG, product size 464 bp), and DAP12 (Forward Primer: 
GTGCCTTCTGTTCCTTCCTG and Reverse primer: 
GGCATAGAGTGGGCTCATCTG, product size 335 bp) using a program of 95°C 
for 3 min, 30 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 1 minute. Transcript 
expression levels were normalised to the expression of GAPDH (Forward Primer: 
CGGAGTCAACGGATTTGGTCGTAT, Reverse primer: 
AGCCTTCTCCATGGTGGTGAAGAC, product size 500 bp). PCR products were 
separated on 1.5 % agarose gels and photographed under UV illumination.  
In situ hybridisation (ISH) 
Brain tissues were prepared for in situ hybridization and probed as described 
previously [40]. 
Synthesis of DIG labelled probes for ISH 
To synthesize digoxigenin (DIG)-labeled RNA probes, the target TREM2 cDNA was 
amplified by PCR using primers designed on the basis of the mouse TREM2 cDNA 
sequence used in RT-PCR. The primers used for DIG labeling were  
 (TREM2-insF: TAATACGACTCACTATAGG GCTGCTGATCACAGCCCTG and  
TREM2-insR: ATTTAGGTGACACTATAGAGGCATAGAGTGGGCTCATCTG).  
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The PCR product was amplified using a 5′ primer containing a T7 phage promoter 
sequence and a 3′ primer containing an SP6 phage promoter sequence, generating a 
template for transcription of a sense and an antisense probe, respectively. The PCR 
products (470 bp) were sequenced and homology checked by BLAST search (NCBI 
database). In vitro transcription reactions were performed using dig-UTP RNA 
labeling mix (Roche, Mannheim, Germany) and SP6 or T7 RNA polymerase (Roche).  
ISH with DIG labelled probe 
Brain, liver and other sections were fixed in 4% PFA for 10 min, permeabilized for 10 
min in PBS with 0.5% Triton X-100 and acetylated by 10 min incubation in a solution 
made of 250 ml of water with 3.5 ml of triethanolamine and 625 µl of acetic 
anhydride added drop wise [40]. Pre-hybridization was performed in hybridization 
buffer made of 50% formamide, 5 × SSC and 2% blocking reagent (Roche) for 3 
hours at 62°C. Hybridization with DIG-labeled probes (100 ng/ml) was performed in 
the same buffer overnight at 62°C. Stringency washing was performed in 0.2 × SSC 
for 1 hour at 62°C. For the detection of DIG-labeled hybrids, the slides were 
equilibrated in maleic acid buffer (0.1 M maleic acid and 0.15 M NaCl, pH 7.5), 
incubated for 1 hour at room temperature with 1% blocking reagent made in maleic 
acid buffer (blocking buffer), and then for 1 hour with alkaline phosphatase-
conjugated anti-DIG antibodies (Roche) diluted 1:5000 in blocking buffer. The slides 
were washed twice for 30 minutes in maleic acid buffer and incubated overnight in 
colour development buffer [2.4 mg levamisole (Sigma), 45 µL 4-nitroblue tetrazolium 
(Sigma) and 35 µl 5-bromo-4-chloro-3-indolyl-phosphate (Sigma) in 10 ml of a buffer 
made of 0.1 M Trizma base, 0.1 M NaCl and 0.005 M MgCl2, pH 9.5]. The reaction 
was stopped in neutralizing buffer (0.01 M Trizma base and 0.001 M EDTA, pH 8) 
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and sections mounted in PBS–glycerol and a coverslips applied. Non-specific binding 
was analysed using sense probes (data not shown). 
Sources of antibodies 
The following primary antibodies were raised again mouse TREM2 peptides, goat 
polyclonal (PAB) anti-TREM2 (ab95470) or rabbit polyclonal anti-TREM2 
(ab175525) and for human cell line mouse monoclonal (Ab201621).  Other antibodies 
used include anti-TREM2 (HPA010917, Sigma-Aldrich), rabbit PAB synaptophysin, 
rabbit PAB synapsin (from Abcam, Cambridge, UK). The monoclonal anti-aβ 
antibodies (6E10) (Signet laboratory) had been described previously [10]  and rabbit 
anti-aβ (1-40) and CD11b (Millipore), anti-GFAP (Sigma-Aldrich), Iba1 (WAKO) 
are described in Table 1. Alexa Fluor 568-labelled donkey anti-mouse, Alexa Fluor 
488-labelled donkey anti-rabbit, and Alexa Fluor 568-labelled donkey anti-goat (all 
from Invitrogen, 1:1000 for IF). 
 
SDS-PAGE and western blotting 
Protein lysates were prepared from cortex of mouse brains (n =6), from primary cell 
culture and neuronal cell line (n=3). 20 µg protein samples were separated on 4-12% 
Nu-PAGE Bis-tris (Bis (2-hydroxyethyl)-amino-tris (hydroxymethyl)-methane) 
gradient gels and transferred to 0.2 µm pore size PVDF membranes, using NuPAGE 
electrophoresis system (Invitrogen). Membranes were incubated with the with 
TREM2 (rabbit polyclonal anti-TREM2 (ab175525) antibody in blocking buffer for 
24 h at 4°C and then washed three times with 0.1 M tris saline buffer containing 1% 
Tween 20 (TBST) followed by incubation for 1 hour at room temperature with HRP-
conjugated secondary antibodies (anti rabbit IgG (1:3000, DAKO) or anti-mouse IgG 
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(1:3000; DAKO) antibodies). Binding was detected with ECL Plus 
chemiluminescence reagents.  
Immunofluorescence (IF) 
Sections were blocked using blocking buffer (0.1 M PBS, 0.1% Triton X100, 10% 
normal donkey serum) for 1 h at room temperature, then incubated overnight at 4°C 
with primary antibody diluted in blocking buffer. Alexa Fluor-conjugated secondary 
antibodies were used for detection and samples counterstained with 4′6-diamidino-2-
phenylindole (DAPI, Sigma). Sections were then mounted on glass slides with 
coverslips using FluorSave (Calbiochem). 
Primary Rat hippocampal cultures  
 
Cultures of dissociated hippocampal neurons were prepared using previously 
described methods [42] with some modifications. Hippocampal tissue was collected 
from Sprague-Dawley (SD) rat embryos (Charles River) at day 18 of development, 
digested in 0.25% trypsin for 15 min at 37 ˚C in Hank’s buffered saline solution 
(HBSS) and then gently triturated in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum and an additional 0.8% of glucose. This 
produced a single cell suspension that was plated at a density of 5x104 cells/cm2 on 
glass coverslips coated with 250µg/ml of poly-D-lysine (PDL, Sigma). Cultures were 
maintained in Neurobasal medium supplemented with 2% B27 and 1% GlutaMAX, 
and used in experiments after 3 – 4 weeks in culture.  Coverslips were fixed with 80% 
ice-cold methanol and analyzed by IF staining as above and examined by confocal 
microscopy. All cell culture media and reagents were purchased from Invitrogen.  
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Neuronal cell lines 
 
Neuronal cell lines (SKNF1 and SH5SY) were plated on PDL coated glass cover slips 
(as described above) in 24 wells plate with Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco), 10% fetal calf serum and 1% penicillin–streptomycin–fungizone 
(PSF). After 1-3 days in vitro cells were fixed with 80% ice-cold methanol and 
analyzed by IF.  
 
 
Primary rat microglial culture and LPS treatment 
The cortices of new-born SD rats (between P1 to P5) were removed, stripped of the 
meninges and then chopped up with a razor blade and incubated in 0.1% trypsin 
(Sigma) in EDTA for 45 min at 37 °C. Following a 5 min incubation in DNAse 
(0.001%, Sigma in HBSS), the supernatant was removed and tissue triturated in 2 ml 
of triturating solution with a flame-polished Pasteur pipette. After centrifugation for 
3 min at 1000 g, cells were re-suspended in culture medium [in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco), 10% fetal calf serum, Sera Lab, UK; 1% 
penicillin–streptomycin–fungizone (PSF), Gibco] and plated in 75 cm3 poly-l-lysine-
coated tissue culture flasks (Nunclon, Life Technologies, Paisley, Scotland) at a 
density of 2 cortices per flask. To prepare the microglial culture, after the cells 
became confluent mixed glial cultures were agitated on a rotary shaker at 200 r.p.m 
for two hours. Floating microglial cells were washed and re grown in a 75 cm3 flask 
and some cells were plated on 13-mm-diameter poly- l-lysine-coated coverslips at a 
density of 104 per coverslip. After 1-3 days in vitro the culture medium in each well 
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was changed, and the cells were treated for 4 h with 100nM of LPS and then washed 
with PBS and fixed as described above.  
Microscopy 
Bright field images were taken and quantified using Lucia imaging software and a 
Leica FW 4000 upright microscope equipped with a SPOT digital camera. 
Fluorescence images were obtained using a Leica DM6000 wide field fluorescence 
microscope equipped with a Leica FX350 camera and x20 and x40 objectives. Images 
were taken through several z-sections and de-convolved using Leica software. A 
Leica TCS SP2 confocal laser-scanning microscope was used with x40 and x63 
objectives to acquire high-resolution images. 
Image and statistics analysis 
All experiments were performed in triplicate. Western blot and immunofluorescence 
images were quantified using ImageJ software (NIH). For Western blots, the gel 
analyzer module was used. Selected bands were quantified based on their relative 
intensities, adjusted for background with fold-change in intensity subjected to 
statistical analysis as described below. Immunofluorescence was quantified using 
methods previously described [16]. Values in the figures are expressed as mean ± 
SEM. To determine the statistical significance, values were analyzed by Student’s t-
test when comparing difference between case (APP-PS1 brain) and controls. A 
probability value of p<0.05 was considered to be statistically significant. 
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Results: 
TREM2 in wild-type mouse brain  
As a first step in determining possible roles of TREM2 in the brain, we have 
investigated the expression of TREM2 and its binding partner DNAX-activating 
protein of 12kDa (DAP12, also called TYROBP) in wild-type (WT) mouse brain over 
time. DAP12 is a type I transmembrane adapter proteins which forms a molecular 
complex with TREM-2 [17, 27]. RT-PCR of TREM2 and DAP12 was performed on 
tissues from the frontal cortex of 3, 6, 9 and 12 months old WT mice (n = 6 per 
group). TREM2 levels demonstrated a gradual increase over time in the control mice, 
peaking at 9 months of age (Figure 1a). DAP12, on the other hand, remained 
consistent over time (Figure 1b), significantly higher than TREM2 at 3 and 6 months. 
These measures indicated that both TREM2 and DAP12 are present in the brain. 
To investigate the cellular localization of TREM2 mRNA in situ hybridization 
experiments were performed using a TREM2 probe (470bp) amplified by DIG 
labeling. Despite the presence of RNA based on RT-PCR, very little TREM2 signal 
was detected in the cortex of WT mice (Figure 1e). Low levels of signal was observed 
around blood vessels in the brain (Figure 1f), with strong TREM2 transcripts inside 
the blood vessels, specifically in the mononucleated cells (Figure 1h). Specificity of 
our probes was demonstrated by labelling TREM2 transcripts in bone osteoclast cells 
(Figure 1i) and in the stellate macrophages or Kuffer cells of the liver (Figure 1g; [43, 
44] and a β-actin probe was used on sections from hippocampus to assess 
hybridization stringency (Figure 1j). Given the limited localisation of TREM2 mRNA 
in brain parenchyma, these data suggest that TREM2 is being derived from elsewhere. 
WB analysis of frontal cortex from WT mice (at 3, 6, 9 and 12 months, n= 6 per 
group) complemented the RT-PCR results, indicating that levels of TREM2 protein 
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increased over the first 6 to 9 months of life (Figure 1k-l). We confirmed the presence 
of TREM2 protein in the WT mouse brain using immunofluorescent staining. In six-
month-old control brains, TREM2 was present in periglomerular neurons, granule 
cells and white matter tracts of the olfactory bulb (Figure 2a). Similar to the in situ 
staining, we noted TREM2 immuno staining close to blood vessels, demonstrating co-
localized with β-catenin and NG2 positive glia (Figure 2b-c). TREM2 protein was 
observed in the granular cells of the dentate gyrus in the hippocampus (Figure 2b-c), 
co-localising with DAPI, whereas no co-localisation with GFAP positive astrocytes 
and minimal co-localisation with Iba1 positive microglia (Figure 2e-f). TREM2 
protein was also present in the cytoplasm and in membrane of the epithelial cells of 
choroid plexus (Figure 2g-h). Interestingly, TREM2 protein was visible in the 
pyramidal neurons of layer V-VI of the cortex and it co-localised with Aβ40 (Figure 
2d). This finding suggested that TREM2 protein was present in the neurons, in the 
oligodendrocytes (in WMT), NG2 positive glia whereas absent in the astrocytes.  
TREM2 expression in APP mouse brain declined with disease 
progression  
Given the co-localisation of TREM2 and Aβ40 in the cortex, we next analyzed the 
expression of TREM2 in the APP-PS1 mice. RT-PCR of frontal cortex tissue from 3, 
6, 9 and 12 months of age, indicated that TREM2 levels were consistently higher in 
APP-PS1 mice than controls, significantly so at 3 months and 12 months (p <0.001; 
Figure 1a). Curiously there was no significant difference in DAP12 mRNA levels 
between the two groups of mice at any time point (Figure 1b). And when we 
compared TREM2 and DAP12 mRNA in the APP-PS1 brain samples, we noted 
significantly higher levels of DAP12 at 3 months of age (p <0.0001, Figure 1c). 
GAPDH was used as an internal control (Figure 1d). When we analyzed at protein 
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levels (via WB), however, we found that TREM2 levels decreased with age and 
disease progression in the APP-PS1 mice  (Figure 1k-l, p= <0.001), suggesting post-
transcriptional issues for TREM2 in these mice. 
To verify further TREM2 protein expression (is it present either in neurons or glial 
cells?) total cell lysates (within 48 hours of culture) from primary cultures of 
microglia, mixed glia (includes astrocytes and oligodendrocytes), primary 
hippocampal culture and a neuronal cell line (SH5SY) were analyzed with mouse 
monoclonal anti-TREM2 antibody (Ab201621). TREM2 expressed in all proliferative 
cells, and highest amounts were in hippocampal neurons (Figure 1m). As only two 
samples were used from each type of cell culture experiments, no statistical analysis 
was performed. These data confirmed that TREM2 protein was present in early stages 
of cellular proliferation including in neurons.  
TREM2 protein in the meningeal macrophages and in surviving 
neurons in APP-tg mouse brain  
Immunofluorescent staining in the 10 month old APP-PS1brain presented prominent 
accumulation of intra-neuronal amyloid throughout the cortex including the frontal 
and entorhinal cortex, and subiculum and CA1 of the hippocampus (Figure 3a-d). 
Similar to the WT situation, in ten months old brain TREM2 protein was found to be 
close to blood vessels (Figure 3e-f). There appeared to be more TREM2 and Aβ42 co-
localisation in cell bodies of the cortex of the APP-PS1 mice, only in surviving 
neurons (Figure 3a-d). Co-labelling of TREM2 and Aβ42 was also present in the 
CA1/2 region of hippocampus (Figure 3a-e), and in close proximity to the plaques in 
that region, in some cases in the centre of plaques that did not co-localised with 
GFAP (Figure 3f). Clear expression of TREM2 was seen in the white matter tract of 
the corpus callosum (Figure 3c), and co-localised with Aβ42 in the ependymal cells 
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of choroid plexus (CP; Figure 3g-h). Of interest to us was the presence of TREM2 
staining in macrophages on the pial surface of the cortex (indicated by * in Figure a-
b) and in perivascular macrophages in the sub-ventricular zone (SVZ; Figure 3g). 
This observation - and the blood vessel staining - provided further indications that 
TREM2 protein is entering the brain via blood vessels and peripheral macrophages. 
TREM2 protein present in perivascular macrophages in the choroid plexus and 
the ventricular wall in APP-PS1 mice 
Given the high levels of TREM2 protein expression in blood vessels, SVZ and CP, 
we turned our attention to the glial cell types in these regions better characterise how 
TREM2 may be entering the brain. We analyzed sections from 6 and 10 month old 
APP-PS1 and WT mice. At the 6 months time point, TREM2 protein exhibited 
limited co-localisation with Iba1+ microglia in the CP of both WT (Figure 4a-c) and 
APP-PS1 mice (Figure 4d-f). Utilising another microglial marker (CD11b), we also 
found no co-localisation with microglial cells in both strains of mice (Figure 4g).  
Astrocytes are also present in the CP and close to blood vessels, but brain sections 
stained with TREM2 indicated no co-localisation with GFAP (Figure 4h). To 
determine entry of TREM2 via blood vessels another section from mid brain stained 
with TREM2 and IL-10, both protein co-localised in the glial cells (figure 4i). This 
data suggested that soluble TREM2 protein enters in the brain parenchyma from 
ventricles, CVO via radial glial cells and was not present in the Iba1 positive activated 
microglia found in the late stages of disease progression as previously reported by 
others [28]. 
 17 
TREM2 expression in primary neurons, neuronal cell lines and glial 
precursors  
In order to investigate possible functional roles of TREM2 in the brain, we 
endeavoured to develop an in vitro assay that could be manipulated. The first step in 
this process is demonstrating that TREM2 is expressed in vitro. Previous reports have 
demonstrated limited TREM2 expression in cortical and hippocampal neuronal 
cultures [26]. In our hands, however, TREM2 was observed in hippocampal neurons 
(Figure 5a-f), particularly in the soma, at perinuclear location, in axons, dendrites and 
in the synapses, co-localised with synaptic vesicular protein synaptophysin (Figure 
5a-c) and synapsin, indicating soluble TREM2 transportation via axon and dendrites 
(Figure 5d-f). We confirmed these observations in a second neuronal cell line 
(SKNF1) noting that both TREM2 and β-III tubulin were seen at perinuclear locations 
(Figure 5g). To determine TREM2 expression glial precursors (OPC), we analysed 
mixed glial cultures in very early stages (within 48 hours of plating).  TREM2 was 
present in the perinuclear cytosol in astrocytes and in the growth cones of 
oligodendrocytes (Figure 5h-i). To confirm TREM2 present was in neuronal precursor 
(NPC), hippocampal culture (within 48 hours of plating) was stained with BIIIT and 
TREM2, it was present in newly proliferative cells, whereas BIIIT was visible in 
mature neurons (Figure 6a). TREM2 protein was visible in glial precursors (OPC) and 
co-localised with SOX2 a know transcription factor present in OPC (Figure 6b-c). An 
astrocyte culture was stained with GFAP and TREM2. A single neuron was stained 
with TREM2 (shown with an arrow) but no co-localisation of TREM2 in mature 
astrocytes (Figure 6d). In oligodendrocytes culture TREM2 was visible in the 
processes and some co-localisation with OPC marker Olig2 in the nucleus (Figure 6 
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e). This data confirmed that TREM2 was present in all proliferative cells and even in 
glial precursor cells.  
In a third neuronal cell line (SH5SY), we observed TREM2 protein present in the 
growth cones, suggesting that TREM2 may have important role in cellular 
differentiation (Figure 6 f-i).  
TREM2 protein was localized in the Golgi complex and in early 
endosomes  
As we have noticed TREM2 protein was visible in perinuclear location, duel labeling 
of TREM2 and Golgi marker (58K-Golgi) was performed in the SKNF1 cell line. 
TREM2 was observed to co-localize with 58K-Golgi in the trans-Golgi location, 
suggesting a function in sorting and packaging proteins for secretion (Figure 6j-l). 
Punctuate TREM2 proteins in the radial glial cells close to the ventricles were 
observed (Figure 4h), therefore SKNF1 cells were stained with TREM2 and an early 
endosome marker EEA1. Duel Immunofluorescence labeling shows that both proteins 
co-localized in the endosomes (Figure 6m-o).  EEA1 localizes exclusively to early 
endosomes and has an important role in endosomal trafficking. Our results suggest 
that TREM2 protein is transported via EEA1 and is a tethering molecule that provides 
directionality to vesicular transport from the plasma membrane to the early 
endosomes.  
Microglia cultures and responds to LPS treatment 
Finally we assessed TREM2 expression in newly proliferative microglia cultures 
(Figure 7a-c), and using higher magnification we found TREM2 was visible in the 
nucleus and perinuclear location but not in the processes and showed limited co-
localisation with microglial marker CD11b (Figure 7d-f). These data provided the 
foundation for investigating roles of TREM2 in vitro. 
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Inflammation is an important part of neurodegenerative conditions, like Alzheimer's 
disease [45]. Thus we began our investigation into TREM2 functions by analysing the 
association of TREM2 in inflammation.  Microglia culture was treated with 100 nM 
of LPS on culture medium for 4 hours. Post-LPS treatment TREM2 expression was 
increased in some newly proliferative microglia, while mature microglia lost the 
perinuclear localisation and limited co-localisation was seen with CD11b (Figure 7g-
i). We also assessed pro-inflammatory cytokines (IL-1β, TNFα and IL-10) in 
untreated and in the LPS treated microglia cultures.  In untreated microglia, pro-
inflammatory cytokines (IL-1β, TNFα) and IL-10 were expressed in the different 
subset of organelles within the cells  (Figure 7J-k & m). TNFα were expressed in a 
different population of microglia that had minimal co-localized TREM2 (Figure 7j) or 
IL-1β (Figure 7k). After LPS treatment both IL-1β and TREM2 proteins was found to 
be spread throughout the membrane in addition to a change to activated microglial 
morphology (loss of processes) and limited co-localisation with IL-1β, (Figure 7l). In 
normal microglia a population of microglia co-localised with CD11b and IL-10 
(Figure 7m). After LPS treatment TREM2 co-localized with IL-10 in mixed glial cells  
(Figure 7n). A significant increase in both TREM2 and IL-1β was detected after LPS 
treatment (Figure 7o, =P < 0.0001) 
 
Discussion  
The association of TREM2 mutations to an increased risk of AD has emphasised the 
important role played by neuroinflammation in neurodegenerative diseases [19, 20, 
46].   Microglia are the only immune cells present in the CNS parenchyma and are the 
quick responders to environmental changes by playing a critical role in clearing debris 
and restoring homeostasis in the CNS [47, 48]. With age, the brain undergoes a 
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homeostatic shift and gradually neuroinflammatory changes develop which 
compromise neuronal function [29, 49].  In the human brain, TREM2 protein is 
involved in bone homeostasis, phagocytosis and migration [27, 50, 51]. 
We have examined TREM2 mRNA levels (by RT-PCR) in APP-PS1 mice and found 
that TREM2 transcription was age related and increased with age. This could be due 
to infiltrating macrophages, and such inflammatory changes and have been described 
in aged APP-PS1 mice which correlate with synaptic function, or it could be due to 
excessive microglial proliferation due to inflammatory changes in early disease 
processes [52]. This findings are supported by others published data on TREM2 
expression in AD transgenic mice [53]. To identify the cellular location of TREM2 an 
in-situ hybridisation was performed in C57/BL6 WT mouse brain with DIG labelled 
TREM2 probe. Surprisingly, very limited cellular expression of TREM2 RNA in the 
mouse brain was visible only in some cells close to blood vessels in the brain 
parenchyma and not present in microglia. This could be due to a limited detection 
level of microglia with DIG labelled probes, however there was a clear signal in the 
blood/myeloid cells. TREM2 protein expression as measured by Western blotting was 
also age-dependent in APP-PS1mice and TREM2 protein levels decreased with age.  
As we have observed that TREM2 protein is expressed in all precursor cells including 
in neuronal precursor cells (NPCs) and glial precursor cells (OPCs), it may therefore 
be involved in cellular proliferation implying that TREM2 deficiency would result in 
impaired interactions between microglia and plaques as previously reported [54, 55].  
TREM2 expression is important in limiting neuronal toxicity during the early stages 
of Aβ deposition. Only one published paper has thus far reported that TREM2 protein 
was present in neurons in human brain close to a blood vessels [28]. We have shown 
that in young WT mice TREM2 protein was highly expressed in the pyramidal 
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neurons, in the hippocampus and dentate gyrus granule cells, suggesting involvement 
in cellular plasticity. With age and disease progression TREM2 levels decreased 
particularly in the frontal and entorhinal cortex, affecting clearing process and plaque 
burden as seen in APP-PS1mice and late onset Alzheimer’s disease. TREM2 protein 
was visible in the choroid plexus epithelial cells and in the peripheral macrophages 
close to the ventricles and subarachnoid space suggested soluble protein carried by 
macrophages before traversing into the brain. We have shown TREM2 and Aβ42 to 
be located in surviving neurons very close to plaques in 3 to 6-month old APP-
PS1mice, whereas with disease progression by 10 months, large swollen dystrophic 
neurites were associated with Aβ plaques and where no TREM2 was detected. 
Although Iba-positive activated microglia were clearly visible in the APP-PS1 and 
WT brain, may be involved in phagocytosis and clearance of plaques. In six-month 
old WT brain TREM2 was present in the radial glial cells close to the CVO and 
ventricular walls not co-localising with Iba1, supporting the notion that soluble 
TREM2 enters in the brain parenchyma via peripheral macrophages as reported 
previously [38].  
In young WT mice TREM2 protein was present in neurogenic niches, therefore we 
grew primary hippocampal neuron culture to show that TREM2 co-localised with 
synaptophysin (presynaptic protein) and synapsin (synaptic vesicular protein) in the 
soma, axon and dendrites. We hypothesised that soluble TREM2 protein could be 
transported through synaptic vesicles may have a role in synaptogenesis or 
neurogenesis.  TREM2 protein was visible in oligodendrocytes, in the white matter 
tracts in the cortex, in the olfactory bulb and in striatal bundles indicating that 
TREM2 protein has a role in myelination so a lack of TREM2 function could be 
involve in demyelination in demyelinating disorders such as Nasu–Hakola disease, 
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multiple sclerosis and amylotropic lateral sclerosis [31, 46].  TREM2 protein was 
visible in the nucleus and perinuclear area (within the Golgi complex) of all primary 
cells (OPC and NPCs) and the highest level was seen in growth cone of neurons and 
oligodendrocytes, further supporting the role of TREM2 in cell proliferation.  
In human and mouse neurons and microglia as well as in human cell lines (microglia 
and glioblastoma), the receptor is mostly localized not at the surface but within the 
cell: in the perinuclear area in neurons and spread throughout the cytoplasm in 
microglia and cell lines [56]. The present work has been carried out in neuronal cell 
line (SKNF1) using immunofluorescence techniques.  TREM2 co-localised with the 
Golgi marker 58K-Golgi, suggesting it may be involved in sorting and packaging of 
proteins for secretion. It could be involved in the transport of lipids around the cell 
that when the process was impaired increased the plaques burden in AD. We have 
seen punctuate TREM2 protein in the radial glial cells close to the ventricles, 
Therefore we investigated location of TREM2 in endosomes, using a SKNF1 cell 
line. TREM2 was found to co-localize with an exclusively early endosome marker 
EEA1.  It may present in late endosome too, at present we are investigating role of 
TREM2 in different endosomal compartment (unpublished findings). 
Our results suggest that TREM2 like EEA1 is a tethering molecule that provides 
directionality to vesicular transport from the plasma membrane to early endosomes. 
TREM2 is mostly distributed intracellular in two pools: a deposit in the Golgi 
complex and a population in endo/exocytic vesicles that are continuously translocated 
to, and recycled from the cell surface as reported previously in a microglia cell line 
[57]. The identification of TREM2-positive vesicles as organelles competent for 
regulated exocytosis might open new insights into the study of membrane trafficking 
and secretion in neuronal cells. 
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The pro-inflammatory cytokines interleukin-1β (IL-1β) and tumour necrosis factor-α 
(TNF-α) are secreted by activated parenchymal microglial cells and are potent 
inducers of cell death in animal models of neurodegeneration [58, 59].  Dysfunctional 
microglia and peripheral macrophages have been shown to contribute to the disease 
progression in an animal model of ALS [60]. Although innate immune response in the 
CNS has detrimental effects it was suggested that it has beneficial role too. The 
release of pro-inflammatory cytokines after acute trauma is followed by a temporal 
production of neurotrophic factors such as ciliary neurotrophic factor (CNTF) and 
insulin-like growth factor 1 (IGF1), both involved in the repair of the injured CNS 
[61]. The presence of TREM2 in the early stages of inflammation and its reduction 
with age suggests that it might be involve in repair and proliferation [62]. IL-10 is an 
anti-inflammatory cytokines involved in repair and found to be reduced in AD brain 
[63]. 
TREM2 was present in the nucleus in early stages of microglial proliferation. After 
LPS treatment TREM2 expression increased in newly proliferative microglia and it 
did not co-localise with TNF-α or IL-1β whereas it co-localised with IL-10 
suggesting that TREM2 might have selective anti-inflammatory roles; currently we 
are investigating possible anti-inflammatory role of TREM2. Furthermore, there 
might be a physiological function of innate immune mediators, too.  
However the functional relevance of innate immune responses in the Alzheimer’s 
disease is not fully understood [64]. It is not clear which components of the innate 
immunity are leading to neurodegeneration and which parts of the innate immune 
response are acting neuroprotectively or even neurodegeneratively.  
Conclusion:  
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We have shown that TREM2 is a serum protein transported by macrophages through 
ventricle walls, CVO and blood vessels entering the brain parenchyma via radial glial 
cells. TREM2 protein is essential for neuroplasticity, neurotrophism and myelination. 
Later in life a lack of TREM2 protein may accelerate the ageing process and neuronal 
cell loss. In all ageing diseases TREM2 levels declined and lack of TREM2 reduced 
microglial activity leading to neuro-inflammation. As inflammation plays a major role 
in neurodegenerative diseases, a lack of TREM2 could be the missing link between 
immunomodulation and neuroprotection.  
 
 
 
 
Abbreviations 
OB, Olfactory bulb; CP, Choroid plexus; CC, Corpus callosum; CVOs, 
Circumventricular organs; DAPI, 4′6-diamidino-2-phenylindole; DG, Dentate gyrus; 
GFAP, Glial fibrillary acidic protein; IHC, Immunohistochemistry; IF, 
Immunofluorescence; PBS, Phosphate saline buffer; PFA, Paraformaldehyde; PVDF, 
Polyvinylidene difluoride; SFG, Superior frontal gyrus; SVZ, Sub ventricular zone; 
TBST, Tris saline buffer with tween; WB, Western blotting; wild type; WT. 
Competing interest  
The author declared that they have no competing interest. 
Author’s contribution 
 25 
 
AAR, JH performed cell culture, Western blotting, IHC and characterization of APP-
PS1 mouse model, IF and confocal microscopy. SS and SF performed in situ, IF and 
statistical analysis. RV, SS and RPF contributed to the hypothesis development and 
implications of inflammation in AD brain pathology and edited the manuscript. SZ 
and RRC contributed to the hypothesis development, performed study design, 
critically evaluated the results and wrote the manuscript. All authors read and 
approved the final manuscript. 
 
Acknowledgements 
This research was funded by Medical research council (MRC grant number is 
RNAG/254), National Institute of Health Research (NIHR), The John Van Geest 
foundation and Cambridgeshire and Peterborough Foundation NHS Trust, 
Cambridge, UK. We would like to thank Professor Antony Holland for his 
encouragement and support, Miss Kirah Goldberg, summer student from University 
of Montreal for participating in histology techniques and to Abcam, Cambridge for 
providing us TREM2 and other antibodies.  
 
 
References:  
 
1. Hardy, J., K. Duff, K.G. Hardy, J. Perez-Tur, and M. Hutton, Genetic 
dissection of Alzheimer's disease and related dementias: amyloid and its 
relationship to tau. Nat Neurosci, 1998. 1(5): p. 355-8. 
2. Selkoe, D.J., D.S. Bell, M.B. Podlisny, D.L. Price, and L.C. Cork, 
Conservation of brain amyloid proteins in aged mammals and humans with 
Alzheimer's disease. Science, 1987. 235(4791): p. 873-7. 
 26 
3. Kim, Y.S. and T.H. Joh, Microglia, major player in the brain inflammation: 
their roles in the pathogenesis of Parkinson's disease. Exp Mol Med, 2006. 
38(4): p. 333-47. 
4. Whitton, P.S., Inflammation as a causative factor in the aetiology of 
Parkinson's disease. Br J Pharmacol, 2007. 150(8): p. 963-76. 
5. Hirsch, E.C., S. Vyas, and S. Hunot, Neuroinflammation in Parkinson's 
disease. Parkinsonism Relat Disord, 2012. 18 Suppl 1: p. S210-2. 
6. Moller, T., Neuroinflammation in Huntington's disease. J Neural Transm 
(Vienna), 2010. 117(8): p. 1001-8. 
7. Holmoy, T., T cells in amyotrophic lateral sclerosis. Eur J Neurol, 2008. 
15(4): p. 360-6. 
8. Frohman, E.M., M.K. Racke, and C.S. Raine, Multiple sclerosis--the plaque 
and its pathogenesis. N Engl J Med, 2006. 354(9): p. 942-55. 
9. Engelhardt, B., The blood-central nervous system barriers actively control 
immune cell entry into the central nervous system. Curr Pharm Des, 2008. 
14(16): p. 1555-65. 
10. Raha, A.A., A. Bomford, and R. Raha-Chowdhury, Hepcidin and Ferroportin 
Participate in Iron Clearance from Brain Endothelium: Failure of This 
Process Leads to Iron Accumulation in Alzheimer's Disease. American 
Journal of Hematology, 2013. 88(5): p. E156-E156. 
11. Schwartz, M. and J. Kipnis, Protective autoimmunity and neuroprotection in 
inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci, 
2005. 233(1-2): p. 163-6. 
12. Town, T., V. Nikolic, and J. Tan, The microglial "activation" continuum: from 
innate to adaptive responses. J Neuroinflammation, 2005. 2: p. 24. 
13. Hardy, J. and D. Allsop, Amyloid deposition as the central event in the 
aetiology of Alzheimer's disease. Trends Pharmacol Sci, 1991. 12(10): p. 383-
8. 
14. Spillantini, M.G. and M. Goedert, Tau pathology and neurodegeneration. 
Lancet Neurol, 2013. 12(6): p. 609-22. 
15. Walsh, D.M. and D.J. Selkoe, Oligomers on the brain: the emerging role of 
soluble protein aggregates in neurodegeneration. Protein Pept Lett, 2004. 
11(3): p. 213-28. 
16. Raha, A.A., R.A. Vaishnav, R.P. Friedland, A. Bomford, and R. Raha-
Chowdhury, The systemic iron-regulatory proteins hepcidin and ferroportin 
are reduced in the brain in Alzheimer's disease. Acta Neuropathol Commun, 
2013. 1: p. 55. 
17. Daws, M.R., L.L. Lanier, W.E. Seaman, and J.C. Ryan, Cloning and 
characterization of a novel mouse myeloid DAP12-associated receptor family. 
Eur J Immunol, 2001. 31(3): p. 783-91. 
18. Cannon, J.P., M. O'Driscoll, and G.W. Litman, Specific lipid recognition is a 
general feature of CD300 and TREM molecules. Immunogenetics, 2012. 
64(1): p. 39-47. 
19. Guerreiro, R. and J. Hardy, TREM2 and neurodegenerative disease. N Engl J 
Med, 2013. 369(16): p. 1569-70. 
20. Jonsson, T. and K. Stefansson, TREM2 and neurodegenerative disease. N 
Engl J Med, 2013. 369(16): p. 1568-9. 
21. Tanzi, R.E., TREM2 and Risk of Alzheimer's Disease--Friend or Foe? N Engl 
J Med, 2015. 372(26): p. 2564-5. 
 27 
22. Slattery, C.F., J.A. Beck, L. Harper, G. Adamson, Z. Abdi, J. Uphill, T. 
Campbell, R. Druyeh, C.J. Mahoney, J.D. Rohrer, J. Kenny, J. Lowe, K.K. 
Leung, J. Barnes, S.L. Clegg, M. Blair, J.M. Nicholas, R.J. Guerreiro, J.B. 
Rowe, C. Ponto, I. Zerr, H. Kretzschmar, P. Gambetti, S.J. Crutch, J.D. 
Warren, M.N. Rossor, N.C. Fox, J. Collinge, J.M. Schott, and S. Mead, R47H 
TREM2 variant increases risk of typical early-onset Alzheimer's disease but 
not of prion or frontotemporal dementia. Alzheimers Dement, 2014. 10(6): p. 
602-608 e4. 
23. Hsieh, C.L., M. Koike, S.C. Spusta, E.C. Niemi, M. Yenari, M.C. Nakamura, 
and W.E. Seaman, A role for TREM2 ligands in the phagocytosis of apoptotic 
neuronal cells by microglia. J Neurochem, 2009. 109(4): p. 1144-56. 
24. Kleinberger, G., Y. Yamanishi, M. Suarez-Calvet, E. Czirr, E. Lohmann, E. 
Cuyvers, H. Struyfs, N. Pettkus, A. Wenninger-Weinzierl, F. Mazaheri, S. 
Tahirovic, A. Lleo, D. Alcolea, J. Fortea, M. Willem, S. Lammich, J.L. 
Molinuevo, R. Sanchez-Valle, A. Antonell, A. Ramirez, M.T. Heneka, K. 
Sleegers, J. van der Zee, J.J. Martin, S. Engelborghs, A. Demirtas-Tatlidede, 
H. Zetterberg, C. Van Broeckhoven, H. Gurvit, T. Wyss-Coray, J. Hardy, M. 
Colonna, and C. Haass, TREM2 mutations implicated in neurodegeneration 
impair cell surface transport and phagocytosis. Sci Transl Med, 2014. 6(243): 
p. 243ra86. 
25. Frank, S., G.J. Burbach, M. Bonin, M. Walter, W. Streit, I. Bechmann, and T. 
Deller, TREM2 is upregulated in amyloid plaque-associated microglia in aged 
APP23 transgenic mice. Glia, 2008. 56(13): p. 1438-47. 
26. Kiialainen, A., K. Hovanes, J. Paloneva, O. Kopra, and L. Peltonen, Dap12 
and Trem2, molecules involved in innate immunity and neurodegeneration, 
are co-expressed in the CNS. Neurobiol Dis, 2005. 18(2): p. 314-22. 
27. Humphrey, M.B., M.R. Daws, S.C. Spusta, E.C. Niemi, J.A. Torchia, L.L. 
Lanier, W.E. Seaman, and M.C. Nakamura, TREM2, a DAP12-associated 
receptor, regulates osteoclast differentiation and function. J Bone Miner Res, 
2006. 21(2): p. 237-45. 
28. Satoh, J., N. Kawana, Y. Yamamoto, T. Ishida, Y. Saito, and K. Arima, A 
survey of TREM2 antibodies reveals neuronal but not microglial staining in 
formalin-fixed paraffin-embedded postmortem Alzheimer's brain tissues. 
Alzheimers Res Ther, 2013. 5(4): p. 30. 
29. Poliani, P.L., Y. Wang, E. Fontana, M.L. Robinette, Y. Yamanishi, S. 
Gilfillan, and M. Colonna, TREM2 sustains microglial expansion during 
aging and response to demyelination. J Clin Invest, 2015. 125(5): p. 2161-70. 
30. Paloneva, J., T. Manninen, G. Christman, K. Hovanes, J. Mandelin, R. 
Adolfsson, M. Bianchin, T. Bird, R. Miranda, A. Salmaggi, L. Tranebjaerg, Y. 
Konttinen, and L. Peltonen, Mutations in two genes encoding different 
subunits of a receptor signaling complex result in an identical disease 
phenotype. Am J Hum Genet, 2002. 71(3): p. 656-62. 
31. Thrash, J.C., B.E. Torbett, and M.J. Carson, Developmental regulation of 
TREM2 and DAP12 expression in the murine CNS: implications for Nasu-
Hakola disease. Neurochem Res, 2009. 34(1): p. 38-45. 
32. Xing, J., A.R. Titus, and M.B. Humphrey, The TREM2-DAP12 signaling 
pathway in Nasu-Hakola disease: a molecular genetics perspective. Res Rep 
Biochem, 2015. 5: p. 89-100. 
 28 
33. Hsiao, K., P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. 
Yang, and G. Cole, Correlative memory deficits, Abeta elevation, and amyloid 
plaques in transgenic mice. Science, 1996. 274(5284): p. 99-102. 
34. Ashe, K.H., Learning and memory in transgenic mice modeling Alzheimer's 
disease. Learn Mem, 2001. 8(6): p. 301-8. 
35. Kumar-Singh, S., D. Pirici, E. McGowan, S. Serneels, C. Ceuterick, J. Hardy, 
K. Duff, D. Dickson, and C. Van Broeckhoven, Dense-core plaques in Tg2576 
and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. 
Am J Pathol, 2005. 167(2): p. 527-43. 
36. Ulrich, J.D., M.B. Finn, Y. Wang, A. Shen, T.E. Mahan, H. Jiang, F.R. 
Stewart, L. Piccio, M. Colonna, and D.M. Holtzman, Altered microglial 
response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol 
Neurodegener, 2014. 9: p. 20. 
37. Frautschy, S.A., F. Yang, M. Irrizarry, B. Hyman, T.C. Saido, K. Hsiao, and 
G.M. Cole, Microglial response to amyloid plaques in APPsw transgenic 
mice. Am J Pathol, 1998. 152(1): p. 307-17. 
38. Jay, T.R., C.M. Miller, P.J. Cheng, L.C. Graham, S. Bemiller, M.L. Broihier, 
G. Xu, D. Margevicius, J.C. Karlo, G.L. Sousa, A.C. Cotleur, O. Butovsky, L. 
Bekris, S.M. Staugaitis, J.B. Leverenz, S.W. Pimplikar, G.E. Landreth, G.R. 
Howell, R.M. Ransohoff, and B.T. Lamb, TREM2 deficiency eliminates 
TREM2+ inflammatory macrophages and ameliorates pathology in 
Alzheimer's disease mouse models. J Exp Med, 2015. 212(3): p. 287-95. 
39. Wang, Y., M. Cella, K. Mallinson, J.D. Ulrich, K.L. Young, M.L. Robinette, 
S. Gilfillan, G.M. Krishnan, S. Sudhakar, B.H. Zinselmeyer, D.M. Holtzman, 
J.R. Cirrito, and M. Colonna, TREM2 lipid sensing sustains the microglial 
response in an Alzheimer's disease model. Cell, 2015. 160(6): p. 1061-71. 
40. Raha-Chowdhury, R., A.A. Raha, S. Forostyak, J.W. Zhao, S.R.W. Stott, and 
A. Bomford, Expression and cellular localization of hepcidin mRNA and 
protein in normal rat brain. Bmc Neuroscience, 2015. 16. 
41. Raha-Chowdhury, R., S.R. Andrews, and J.R. Gruen, CAT 53: A protein 
phosphatase 1 nuclear targeting subunit encoded in the MHC Class I region 
strongly expressed in regions of the brain involved in memory, learning, and 
Alzheimer's disease. Molecular Brain Research, 2005. 138(1): p. 70-83. 
42. Marland, J.R., D. Pan, and P.C. Buttery, Rac GTPase-activating protein (Rac 
GAP) alpha1-Chimaerin undergoes proteasomal degradation and is stabilized 
by diacylglycerol signaling in neurons. J Biol Chem, 2011. 286(1): p. 199-
207. 
43. Goncalves, L.A., L. Rodrigues-Duarte, J. Rodo, L. Vieira de Moraes, I. 
Marques, and C. Penha-Goncalves, TREM2 governs Kupffer cell activation 
and explains belr1 genetic resistance to malaria liver stage infection. Proc 
Natl Acad Sci U S A, 2013. 110(48): p. 19531-6. 
44. Otero, K., M. Shinohara, H. Zhao, M. Cella, S. Gilfillan, A. Colucci, R. 
Faccio, F.P. Ross, S.L. Teitelbaum, H. Takayanagi, and M. Colonna, TREM2 
and beta-catenin regulate bone homeostasis by controlling the rate of 
osteoclastogenesis. J Immunol, 2012. 188(6): p. 2612-21. 
45. Heppner, F.L., R.M. Ransohoff, and B. Becher, Immune attack: the role of 
inflammation in Alzheimer disease. Nat Rev Neurosci, 2015. 16(6): p. 358-72. 
46. Lill, C.M., A. Rengmark, L. Pihlstrom, I. Fogh, A. Shatunov, P.M. Sleiman, 
L.S. Wang, T. Liu, C.F. Lassen, E. Meissner, P. Alexopoulos, A. Calvo, A. 
Chio, N. Dizdar, F. Faltraco, L. Forsgren, J. Kirchheiner, A. Kurz, J.P. Larsen, 
 29 
M. Liebsch, J. Linder, K.E. Morrison, H. Nissbrandt, M. Otto, J. Pahnke, A. 
Partch, G. Restagno, D. Rujescu, C. Schnack, C.E. Shaw, P.J. Shaw, H. 
Tumani, O.B. Tysnes, O. Valladares, V. Silani, L.H. van den Berg, W. van 
Rheenen, J.H. Veldink, U. Lindenberger, E. Steinhagen-Thiessen, S. 
Consortium, S. Teipel, R. Perneczky, H. Hakonarson, H. Hampel, C.A. von 
Arnim, J.H. Olsen, V.M. Van Deerlin, A. Al-Chalabi, M. Toft, B. Ritz, and L. 
Bertram, The role of TREM2 R47H as a risk factor for Alzheimer's disease, 
frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and 
Parkinson's disease. Alzheimers Dement, 2015. 11(12): p. 1407-16. 
47. Koizumi, S., Y. Shigemoto-Mogami, K. Nasu-Tada, Y. Shinozaki, K. 
Ohsawa, M. Tsuda, B.V. Joshi, K.A. Jacobson, S. Kohsaka, and K. Inoue, 
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. 
Nature, 2007. 446(7139): p. 1091-5. 
48. Sierra, A., J.M. Encinas, J.J. Deudero, J.H. Chancey, G. Enikolopov, L.S. 
Overstreet-Wadiche, S.E. Tsirka, and M. Maletic-Savatic, Microglia shape 
adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. 
Cell Stem Cell, 2010. 7(4): p. 483-95. 
49. Costello, D.A., K. Keenan, R.M. McManus, A. Falvey, and M.A. Lynch, The 
age-related neuroinflammatory environment promotes macrophage activation, 
which negatively impacts synaptic function. Neurobiol Aging, 2016. 43: p. 
140-8. 
50. Forabosco, P., A. Ramasamy, D. Trabzuni, R. Walker, C. Smith, J. Bras, A.P. 
Levine, J. Hardy, J.M. Pocock, R. Guerreiro, M.E. Weale, and M. Ryten, 
Insights into TREM2 biology by network analysis of human brain gene 
expression data. Neurobiol Aging, 2013. 34(12): p. 2699-714. 
51. Lampron, A., P.M. Pimentel-Coelho, and S. Rivest, Migration of bone 
marrow-derived cells into the central nervous system in models of 
neurodegeneration. J Comp Neurol, 2013. 521(17): p. 3863-76. 
52. Gate, D., K. Rezai-Zadeh, D. Jodry, A. Rentsendorj, and T. Town, 
Macrophages in Alzheimer's disease: the blood-borne identity. J Neural 
Transm (Vienna), 2010. 117(8): p. 961-70. 
53. Matarin, M., D.A. Salih, M. Yasvoina, D.M. Cummings, S. Guelfi, W. Liu, 
M.A. Nahaboo Solim, T.G. Moens, R.M. Paublete, S.S. Ali, M. Perona, R. 
Desai, K.J. Smith, J. Latcham, M. Fulleylove, J.C. Richardson, J. Hardy, and 
F.A. Edwards, A genome-wide gene-expression analysis and database in 
transgenic mice during development of amyloid or tau pathology. Cell Rep, 
2015. 10(4): p. 633-44. 
54. Wang, Y., T.K. Ulland, J.D. Ulrich, W. Song, J.A. Tzaferis, J.T. Hole, P. 
Yuan, T.E. Mahan, Y. Shi, S. Gilfillan, M. Cella, J. Grutzendler, R.B. 
DeMattos, J.R. Cirrito, D.M. Holtzman, and M. Colonna, TREM2-mediated 
early microglial response limits diffusion and toxicity of amyloid plaques. J 
Exp Med, 2016. 213(5): p. 667-75. 
55. Yuan, P., C. Condello, C.D. Keene, Y. Wang, T.D. Bird, S.M. Paul, W. Luo, 
M. Colonna, D. Baddeley, and J. Grutzendler, TREM2 Haplodeficiency in 
Mice and Humans Impairs the Microglia Barrier Function Leading to 
Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron, 2016. 
90(4): p. 724-39. 
56. Sessa, G., P. Podini, M. Mariani, A. Meroni, R. Spreafico, F. Sinigaglia, M. 
Colonna, P. Panina, and J. Meldolesi, Distribution and signaling of 
TREM2/DAP12, the receptor system mutated in human polycystic 
 30 
lipomembraneous osteodysplasia with sclerosing leukoencephalopathy 
dementia. Eur J Neurosci, 2004. 20(10): p. 2617-28. 
57. Prada, I., G.N. Ongania, C. Buonsanti, P. Panina-Bordignon, and J. Meldolesi, 
Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in 
microglial cells: continuous shuttling to and from the plasma membrane 
regulated by cell stimulation. Neuroscience, 2006. 140(4): p. 1139-48. 
58. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias, Immune and 
inflammatory responses in TNF alpha-deficient mice: a critical requirement 
for TNF alpha in the formation of primary B cell follicles, follicular dendritic 
cell networks and germinal centers, and in the maturation of the humoral 
immune response. J Exp Med, 1996. 184(4): p. 1397-411. 
59. Beaulieu, L.M., E. Lin, E. Mick, M. Koupenova, E.O. Weinberg, C.D. 
Kramer, C.A. Genco, K. Tanriverdi, M.G. Larson, E.J. Benjamin, and J.E. 
Freedman, Interleukin 1 receptor 1 and interleukin 1beta regulate 
megakaryocyte maturation, platelet activation, and transcript profile during 
inflammation in mice and humans. Arterioscler Thromb Vasc Biol, 2014. 
34(3): p. 552-64. 
60. Boillee, S., K. Yamanaka, C.S. Lobsiger, N.G. Copeland, N.A. Jenkins, G. 
Kassiotis, G. Kollias, and D.W. Cleveland, Onset and progression in inherited 
ALS determined by motor neurons and microglia. Science, 2006. 312(5778): 
p. 1389-92. 
61. Nguyen, M.D., J.P. Julien, and S. Rivest, Innate immunity: the missing link in 
neuroprotection and neurodegeneration? Nat Rev Neurosci, 2002. 3(3): p. 
216-27. 
62. Kipnis, J. and M. Schwartz, Controlled autoimmunity in CNS maintenance 
and repair: naturally occurring CD4+CD25+ regulatory T-Cells at the 
crossroads of health and disease. Neuromolecular Med, 2005. 7(3): p. 197-
206. 
63. Guillot-Sestier, M.V., K.R. Doty, D. Gate, J. Rodriguez, Jr., B.P. Leung, K. 
Rezai-Zadeh, and T. Town, Il10 deficiency rebalances innate immunity to 
mitigate Alzheimer-like pathology. Neuron, 2015. 85(3): p. 534-48. 
64. Guillot-Sestier, M.V., K.R. Doty, and T. Town, Innate Immunity Fights 
Alzheimer's Disease. Trends Neurosci, 2015. 38(11): p. 674-81. 
 
 
 
 
Figure Legends: 
Figure 1:  TREM2 protein level declined with disease progression in APP-PS1 
mice.  
Fig 1 a-d: RNA analysis by RT-PCR confirmed an age-dependent increase in TREM2 
in the brains of APP and WT mice (a), only statistically significant at 3 and 12 months 
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age (p <0.01), DAP12 levels were not significant (b), comparison of TREM2 and 
DAP12 mRNA was significant (c, p <0.001).  GAPDH was analyzed as an internal 
control (d).  
Fig 1 e-j: In situ hybridization was performed using a DIG labeled TREM2 antisense 
probe. Very low signal was detected in the frontal cortex of mouse brain (e), around 
the blood vessels in striatum (f) and in the liver macrophages (g). Clear expression 
was seen in the blood vessel, specifically in the mononucleated cells, in the brain 
parenchyma (h) and in the bone cells (i).  β-actin probe was used as a positive control 
(j). Scale bar, 150 µm (e), 100 µm (g) and 25µm (f, h) 20 µm (I & j). 
Fig 1 k-m: Western blot (WB) analysis of the brain homogenate from frontal cortex of 
APP-PS1 and WT (c57/Bl6) mice demonstrated a single 25 kDa band consistent with 
TREM2 protein (probed with rabbit polyclonal ab175262) was clearly visible within 
all controls (lane 1; 3m, 2: 6 m, 3: 9 m and 4: 12 m) and APP-PS1 mice (lane 5: 3m, 
6: 6 m, 7: 9 m and 8: 12 m) (k). Densitometric analysis of the blots showed that there 
were significant differences TREM2 levels between APP and control brains were 
higher in controls, decreased in APP-PS1 brain with age (k & l, p= <0.001). 
WB analysis of primary cell culture lysates, (microglia lane 1, 2, mixed glia, lane 3, 4, 
hippocampus, lane 5, 6, neuronal cell line SH5SY, lane 7 and 8) showed that TREM2 
expressed all newly proliferative cells (m). As there were only two cell lysates used 
from each group, statistical analysis not performed. β-Actin loading control was used 
to normalize data.  
 At least three independent experiments were performed for all analyses. Bonferroni-
corrected Student’s t tests shown; n = 6 per group). Error bars indicate SEM. *p<0.05, 
**p<0.01, ***p<0.001, one-way ANOVA. 
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Figure 2: TREM2 protein expression in control mice brain. 
Double immunofluorescence (IFC) staining was performed in six months old control 
mouse brains with goat polyclonal anti-TREM2 (ab95470; red) and monoclonal anti-
GFAP (green) antibodies and counterstained with DAPI for nuclei (Blue). TREM2 
immuno-reactivity was visible in molecular layer of olfactory bulb, in glomerular 
neurons and white matter tracts of the olfactory bulb did not co-localize with GFAP 
positive astrocytes (a). TREM2 protein (red) was expressed throughout cortex, in the 
hippocampus and dentate gyrus and there was some co-localization with β-catenine 
on blood vessels wall (b).  TREM2 was present in the dentate gyrus granule cells and 
some cells co-localized with NG2 (green) positive glia (c). Under higher 
magnification TREM2 protein was visible in the layer V pyramidal neurons (d), in 
individual granule cells co-localizing with DAPI but not with GFAP positive 
astrocytes (e), whereas there was minimal co-localization with microglial marker Iba1 
(f). TREM2 protein was present in the cytoplasm and in the membrane of epithelial 
cells of choroid plexus (g-h).  Scale bar panels a: 50µm, b: 150µm, d & g: 30µm and c 
& e 25µm, f & h: 20µm. 
Figure 3: TREM2 protein in the meningeal macrophages and in 
surviving neurons in APP-PS1 mouse brain. 
Double-label immunofluorescence (IFC) staining of Aβ-42 (green) and TREM2 (red) 
and DAPI for nucleus was performed in coronal sections from cortex of 6-10 month 
old APP-PS1-tg2576 mice. In six-month-old APP-PS1 mice, coronal section from 
frontal cortex (FCX) was stained with TREM2 (red) and Aβ42 (6E10) green and 
DAPI (a-d).  Severe pathology was evident with amyloid plaques increased in size 
and quantity and distributed throughout the cortex, TREM2 was observed around the 
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plaques and in pyramidal neurons, in meningeal marcophages (* points to pial 
vasculature, a b). TREM2 protein was visible in hippocampus (CA1, indicating with 
an arrow) and in sabiculum, in the white matter tract of corpus callosum (c), in 
surviving neurons close to the plaques (d). In ten-month-old APP mice, TREM2 
protein was visible in the blood vessels in close proximity to the plaques, did not co-
localize with Aβ42 positive plaques (e). With disease progression dense plaques were 
visible in the cortex, TREM2 (red) and GFAP (green) positive activated astrocytes 
were present close to the plaques but did not co-localize with TREM2 (f). In six 
months old APP-PS1 mice in the lateral ventricle, TREM2 positive macrophages 
were visible in the choroid plexus, (arrow indicates TREM2 positive macrophages) 
co-localized with Aβ42 (green) in appendemal cells (g). β-catenin and TREM2 were 
visible in the choroid plexus with moderate co-localization and TREM2 positive cells 
were present close in the CVO (h). At least three independent experiments were 
performed for all analyses. Scale bar panels a: 50µm, b and c: 100 µm, d: 15 µm, e & 
f:  25 µm, g & h: 50µm.	
Figure	 4:	 	 TREM2 protein did not co-localize with Iba1 positive 
activated microglia in the choroid plexus.  
Immunofluorescence (IFC) staining of TREM2 (red) and Iba1 (green) was performed 
in six-month-old brain sections from lateral ventricle (LV) with choroid plexus (CP) 
and counterstained with DAPI (blue). Iba1 positive microglias were visible in the 
choroid plexus where minimal co-localization with TREM2 positive cells (a-c). 
TREM2 protein was present in the radial glial cells close to the ventricles and did not 
co-localized with Iba1 positive activated microglia in APP-PS1 mice (d-f).  In higher 
magnification a cortical plaques was stained with CD11b and faint TREM2 
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expression was seen in the centre of the plaques (g). In SVZ, punctuate vesicular 
TREM2 was visible in the wall of ventricle, without any co-localization GFAP (h), 
whereas in the blood vessels TREM2 and IL-10 co-localized (i).	 	scale	bar	 	a-f:	 	50	
µm,	g	:	25µm,	h-l:		30	µm.		
Figure 5: Soluble TREM2 was visible in primary hippocampal 
neurons.  
Confocal microscope analysis of primary hippocampal culture neurons shows that 
synaptophysin (green) expressed in the synapses (a) and TREM2 (red) was present 
membrane bound and perinuclear location (b) and visible axon and dendrites in a 
merge picture (c). Further co-localized with synapsin (d) and TREM2 (e) indicates 
soluble TREM2 transport might via axon and dendrites (f). SKNF1 cells line was 
stained with TREM2 (red) and β-III tubulin (green), TREM2 expression was seen at 
perinuclear whereas β-III tubulin was visible in the process (g). In mixed glial culture 
very early stages, (within 48 hours of plating) TREM2 (red) was present in the 
perinuclear location in the GFAP positive (green) astrocytes (h) and in the growth 
cones of oligodendrocytes indicating with an arrow (i). The	scale	bar	in	a-f	20µm,	g-100µm,	h-i,	25µm.		
Figure 6: TREM2 protein was present in different cellular 
compartments in primary cells and in neuronal cell line.   
Immunofluorescence (IFC) staining of TREM2 (green) and βIIIT (red) was 
performed in NPCs (a) and OPCs (b-c). TREM2 was visible in NPCs cluster (a) and 
in glial precursor (b). TREM2 and SOX2 (red) co-localized in the nucleus of OPCs 
(c). In a glial culture a limited number of neurons were present and stained with 
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TREM2 (red, indicated with an arrow), did not co-localized with GFAP (green) 
positive astrocytes (d). TREM2 staing was visible in  oligodendrocytes and co-
localised with olig2 in the nucleus (e). Neuronal cell line (SH5SY) and stained with 
Aβ40 (green) and TREM2 (red), both proteins were present in the growth cones 
(indicating with an arrow), suggesting that it may have important role in 
differentiation (f-i). In neuronal cell line (SKNF1) TREM2 (red) and 58K-Golgi 
(green) co-localised in the Golgi compartment (j-l) and in early endosome stained 
with EEA1 (green) (m-o). The	scale	bar	in	a	&	e:	50µm,	b-d:	25µm,	f-i	20µm,	i-o:	30µm.	 
Figure 7: Microglia cultures and responds to LPS treatment. 
The newly proliferative microglia (after 24 hours) stained with microglial marker 
CD11b (green) and TREM2 (red) and counterstained with DAPI for nuclear 
localization. Both proteins were visible in the microglia (a-c). In higher magnification 
TREM2 was visible in the nucleus and perinuclear location but not in the processes 
and co-localized with microglial marker CD11b (d-f). In normal microglia, pro-
inflammatory cytokines TNFα (j), IL-1β (k) and IL-10 (m) was expressed in different 
organelles within the cells.  After LPS administration TREM2 expression was 
increased in some newly proliferative microglia, a lost the perinuclear localization in 
mature microglia and limited co-localization with CD11b (g-i). After LPS treatment, 
both IL-1β and TREM2 proteins spread through out the membrane and showed 
activated microglial morphology (loss of processes) and limited co-localization with 
TREM2 and IL-1β  (l) whereas IL-10 and TREM2 co-localized in mixed cell 
populations (n). The fluorescence intensity indicated a significant increased of 
TREM2 and IL-1β after LPS treatment (l, =P < 0.0001). Scale bar in a-c, g-i and m-n: 
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50µm, d-f: 20, j-l: 25µm. Error bars indicate SEM. *p<0.05, ***p<0.001, one-way 
ANOVA. 
Table 1.   List of the primary antibodies used in this study  
 
Antibody Species Dilution Supplier/cat. Number 
Anti-β 42 (6E10) 
 
Mouse 
(monoclonal) 
1: 1000 for IHC 
 
Covance Cat Number 
(SIG 39320) 
Anti-Aβ40 Rabbit 
(polyclonal) 
1: 500 for IHC 
 
Thermo Fisher Scientific 
(44348A) 
Anti-TREM2 Rat 
(monoclonal) 
1: 1000 for IHC 
1:2000 for WB 
Abcam  (Ab86491) 
 
Anti-TREM2 Rabbit 
(polyclonal) 
1: 200 for IHC 
1:1000 for WB 
Abcam (ab175262) 
 
Anti-TREM2 Goat 
(polyclonal) 
1:200 for IHC 
1:1000 for WB 
Abcam (ab95470) 
 
Anti-TREM2 Rabbit 
(polyclonal) 
1: 200 for IHC 
1:1000 for WB 
Sigma-Aldrich 
(HPA010917) 
Anti-DAP12 Rabbit 
(polyclonal 
1:500 for IHC Abcam (ab93846) 
 
Anti β-catenin Mouse 
(monoclonal) 
1: 1000 for IHC BD-Biosciences (610153) 
Anti-GFAP Mouse 
(monoclonal) 
1:1000 for IHC Sigma (G3893 Clone G-A5) 
 
Anti-GFAP Rabbit 1:200 for IHC Abcam (ab48050) 
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(polyclonal)  
Anti-βIII-tubulin Mouse 
(monoclonal) 
1:1000 for IHC Millipore (clone 2G10, 
neuronal | 05-559) 
Anti β-actin Mouse 
(monoclonal) 
1:10000 for WB Sigma (clone AC-74, A5316) 
Anti-CD11b Mouse 
(monoclonal) 
1:1000 for WB 
1:500 for IHC 
Chemicon CBL1512 
Anti-Iba1 
 
Rabbit 
(polyclonal) 
1:500 for IHC Wako (019-19741) 
Anti-IL-1β Goat 
(polyclonal) 
1:200 for IHC R&D system 
(AB-401-NA) 
Anti-TNFα Rabbit 
(polyclonal) 
1:250 for IHC Abcam (ab34674) 
 
Anti-IL-10 Rabbit 
(monoclonal) 
1: 500 for IHC 
1:1000 for WB 
Abcam (ab133575) 
 
Anti-SOX2 Mouse 
(monoclonal) 
1:1000 for IHC Abcam (Ab79351) 
Anti-Olig2 Rabbit 
(monoclonal) 
1:1000 for IHC Abcam (ab109186) 
Anti-EEA1 Rabbit 
(polyclonal 
1: 500 for IHC 
 
Abcam (ab2900) 
 
Anti-58K-Golgi Mouse 
(monoclonal) 
1: 500 for IHC 
 
Abcam (ab27043) 
 
Anti-Synapsin Rabbit 
(polyclonal) 
1: 1000 for IHC 
 
Abcam (ab8) 
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Anti-
Synaptophysin 
Rabbit 
(polyclonal) 
1: 500 for IHC    Abcam (ab32594) 
 
 
IHC, immunohistochemistry; WB, Western blot. 
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